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A REVIEW OF NEUROLEPTIC MALIGNANT SYNDROME~ 

INCIDENCE AND FEATURES IN MALTA 
A. Grech, JR. 5aliha 
ABSTRACT: 
This paper describes Malta's first sample of Neuroleptic Malignant Syndrome (NMS) 
and reviews the current literature. A retrospective sample of all diagnosed cases of 
NMS was reviewed using Pope's (1986) criteria. Twelve cases were identified 
yielding an incidence of 0.67%. The range of associated risk factors and 
complications agreed with other reports. There were also two cases of uncontrolled 
diabetes. Treatments commonly used were Bromocriptine and Levodopa. There 
were no deaths due to NMS and no recurrence on re-exposure. The sample is too 
small to draw any statistically significant conclusions, however, the results are mostly 
in line with those obtained from larger samples. Malta's incidence is towards the 
lower end of the reported range of 0.02% to 3.23%, but higher than that reported in 
centres trying to recognise NMS early and reduce risk factors. This suggests that 
Malta could benefit from trying to adopt such measures. Given Malta's small size, it 
would be relatively easy to disseminate such information. Keck et al describe the 
following measures for the early detection of NMS: i) increase in clinical awareness 
of the cardinal features of NMS; ii) treating neuroleptic induced extrapyramidal 
and autonomic side effects at their earliest emergence; iii) minimising risk factors 
such as the use of intramuscular neuroleptics. The other noteworthy point is the 
previously reported association of non-ketotic diabetic coma with NMS. This study, 
despite its comprehensive sample, failed to reveal any other reported cases. Nor has 
it been demonstrated that diabetics were at higher risk of developing NMS or its 
complications. It would be important to explore these possibilities further in future 
studies. 
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Introduction 
The Neuroleptic Malignant Syndrome (NMS) is 
an uncommon but potentially fatal idiosyncratic 
reaction to neuroleptics. It is characterised by a 
decreased level of consciousness, greatly 
increased muscle tone, and autonomic 
dysfunction including hyperpyrexia, labile 
hypertension, tachycardia, tachyprloea, 
diaphoresis and drooling. Laboratory 
abnormal ities include greatly elevated creatine 
phosphokinase levels and leucocytosis. 
The fact that all neuroleptics implicated in NMS 
share the property of D2 dopamine receptor 
antagonism supports the involvement of 
dopamine in the pathogenesis of NMS. However 
the view that NMS results from dopamine 
blockade is simplistic as it fails to account for the 
rare occurrence of the syndrome and its 
unpredictable onset, even In patients with 
previous episodes. 
Estimates of the incidence of NMS vary greatly 
and have ranged from 0.02% to 3.23% of 
neuroleptic-treated patients. These differences 
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probably reflect differences in diagnostic criteria, 
survey techniq ues, patient populations, clinical 
settings and treatment practices. l Keck et al 
have found an NMS incidence of 0.15 % in a 
prospective study of neuroleptic-treated patients.2 
In an earlier study at the same centre the 
incidence was 1.1 %.3 This decline was attributed 
to earlier recognition and reduction of risk 
factors. Pooling data from 16 studies of 
incidence of NMS in the literature, Caroff and 
Mann found 66 NMS cases among 33 ,720 
neuroleptic-treated patients yielding an incidence
-	 of 0 .2% .4 
The demarcation between mild cases of NMS 
and the spectrum of more benign extrapyramidal 
effects of neuroleptics is very blurred. For this 
reason Pope et al developed operational criteria 
f or the diagnosis of NMS.s According to these, 
the following three items are all required for 
definite diagnosis : 
1. Hyperthermia: Oral temperature of at least 
37.5 0 C in absence of another known 
aetiology . 
2. Severe extrapyramidal effects characteri sed 
by two or more of the following: 
• lead-pipe muscle rigidity 
• pronounced cog-wheeling 
• sialorrhoea 
• oculogyric crises 
• retrocoll is 
• opistothonus 
• trismus 
• dysphagia 
• choreiform movements 
• dyskinetic movements 
• festinant gait 
• flexor-extensor posturing 
3. Autonomic dysfunction characterized by two 
or more of the following: 
• 	 hypertension (at least 20 mm rise in 
diastolic pressure above baseline ) 
• 	 tachycardia (at least 30 beats/ min 
above baseline) 
• tachypnoea (at least 25 resp/ min) 
• prominent diaphoresis 
• incontinence 
In the case of re trospective diagnosis, if one of 
these three items has not been specifically 
documented, a prohahle diagnosis may be made 
if the other two criteria are clearly met and the 
patient displays one of the following 
characteristic signs: 
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• 	clouded consciousness as evidenced by 

delirium, mutism, stupor or coma 

• 	 leucocytosis (> 15,000 WBC/cubic mm) 
• 	 serum creatine kinase level >300 U/L 
Knowing the risk fa ctors for NMS is very 
important in its prevention and Keck et al 
identified factors additional to dopamine 
blockade which are necessary to trigger an 
episode of NMS.2,6 Risk factors can be either 
intrinsic to the patient, or related to the treatment 
used. 
Neither age nor sex can be considered as risk 
factors, but a past history of NMS is a definite 
risk factor. 4 
NMS is not specific to any neuropsychiatric 
diagnosis, but amongst patients with NMS, there 
is a preponderance of affecti ve disorders.7.8 
Affective disorder may reflect a state-dependant 
vulnerability to NMS. Most patients, prior to the 
NMS episode displayed significantly greater 
psychomotor agitation.6.7 It is possible that this 
agitation represents undiagnosed akathisia, which 
might create a state-dependent predisposition to 
NMS. 
Most patients with NMS present in a state of 
dehydration. 7 Dehydration may contribute to the 
development of NMS by increasing the effective 
concentration of neuroleptics in extracellular 
fluids. It may also be an effect of NMS rather 
than a predisposing cause, such dehydration 
being due to fever, diaphoresis an decreased fluid 
intake. 
Nearly half of the patients with NMS suffer from 
an additional form of hrain pathology or 
vulnerability apart from their psychiatric illness .7 
Although it has been suggested that NMS is not 
dose related, both Rosebush & Stewart, and Keck 
et al found the syndrome to occur with higher 
neuroleptic dosage albeit within the normal 
therapeutic range .6.7 
Recent change ill treatment al so constitutes a 
definite risk factor for the development of NMS 
and this change can be either a recent onset or a 
recent increase of treatll1ent. 7 It is not the 
increase in dosage, but the rate of dose increase, 
that is directly related to the deve lopl11cnt of 
NMS.4.6 
In nearly 80% of the cases who de veloped NMS, 
the route of administration of treatl11ent was 
intramuscular4 .6.R Thi s ri sk increased tenfold if 
the neuroleptics werc adlllinistered without al/ti­
parkinsonian agents. 4 
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Most studies report a significantly greater use of 
lithium carbonate in patients who develop 
NMS. l!2,5 There is the possibility that 
neuroleptics combined with lithium carbonate are 
more liable to cause NMS than neuroleptics 
alone. 
The main complications of NMS are 
rhabdomyolysis, respiratory complications, renal 
failure and finally death. 
The mortality rate when only supportive 
measures are used is around 21 %.4 This falls to 
10% when treatment more than mere supportive 
measures is used: for bromocriptine with other 
drugs, the mortality is 10.1 %; for bromocriptine 
alone it is 7.8% and 10.3% for ECT. 
About i5% of cases of NMS have 
rhabdomyolysis which can result in high levels of 
creatine phosphokinase and potassium, 
myoglobinuria and renal insufficiency. Renal 
failure develops in around one fourth of casesJ,9 
Respiratory failure develops in nearly 20% of 
cases. The cause of this is not clear but may 
involve aspiration, infection, shock and 
pulmonary em boli. 9 Other documented and less 
common complications of NMS are: myocardial 
infarction, pulmonary embolus, hepatic failure , 
disseminated intravascular coagulation, sepsis, 
deep vein thrombosis and E.coli fascitis9,IO 
In Malta, Pullicino et al reported two cases that 
developed cerebral infarction,1O whilst Balzan 
and Cacciottolo reported one who developed 
diabetic coma as a complication of NMS.ll 
Very little information exists about the long term 
residual effects of NMS. Three out of the 24 
patients in Rosebush et aI's study had 
parkinsonian symptoms five months after the 
NMS episodeJ 
Most patients with NMS have psychiatric 
disorders that need psychotropic treatment 
ralsmg the question of re-treatment with 
neuroleptics. In most cases neuroleptics can be 
re-introduced safely, but there is a significant risk 
of recurrence. An important variable when re­
challenging with neuroleptics is the time that has 
elapsed since the episode, indeed there is a 
suggestion that two weeks may be the critical 
time lapse.7 The potency of neuroleptics used in 
the re-challenge is the other important factor; a 
30% NMS recurrence rate dropped to 15% when 
lower potency neuroleptics were used.9 
Method and Sample 
A retrospective sample of al1 known cases of 
NMS in Malta was reviewed. The sample was 
obtained by circulating all consultant 
psychiatrists, physicians, and ITU anaesthetists in 
Malta and Gozo, regarding possible cases of 
NMS under their care. All replied yielding 
thirteen possible cases and information about 
these cases was obtained by reviewing their case­
records including whether they fulfilled the Pope 
criteria for NMS: twelve cases were thus 
identified of which ten fulfilled the Pope criteria 
for definite diagnosis of NMS, two patients for 
probable diagnosis and one did not, this latter 
thus being excluded from the study sample. 
The incidence of NMS in neuroleptic-treated 
patients was then calculated for Malta's one 
psychiatric hospital, Mount Carmel Hospital. All 
in-patients diagnosed with NMS at Mount 
Carmel Hospital between the 1st January 1992 
and the 31st December 1993 were collected. To 
calculate the incidence in neuroleptic-treated 
patients it was necessary to estimate how many 
patients were treated with neuroleptics during the 
same period. In line with Pope et aI's study, one 
sixth of hospital admissions were reviewed and 
the proportion of patients on neuroleptics used to 
estimate the proportion on neuroleptics in the two 
year period.5 
Results 
The sample consisted of twelve patients, (seven 
males) with a mean age of 43.6 years (range 16­
80). It was estimated that 596 (56.6%) of the 
1053 patients admitted to Mount Carmel Hospital 
had been on neuroleptics for one week or more of 
which four developed NMS, yielding an 
incidence of 0.67%. 
Of the total sample, one patient did not have any 
mental illness, neuroleptics having been 
prescribed as an anti-emetic. Four patients had 
affective disorder, three of them with psychotic 
features and one was also mental1y retarded. The 
psychiatric diagnosis of the other patients were 
senile dementia in two cases, psychosis in a 
further three cases, one case of mental retardation 
and one of schizophrenia (Table I). One of the 
psychotic cases also had hydrocephalus. Two of 
the cases developed NMS during an episode of 
uncontrolled diabetes mellitus. 
In nine cases, neuroleptics were prescribed by a 
psychiatrist, in one case by a physician and in an 
other by a surgeon. Eight patients developed 
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Clinical Sample 
Case No Primary Change in Total "stat" Duration of Treatment Rechallenge Rechallenge 
Psychiatric regular treatment in last NMS Hospitaliz­ (additional to (time lapse in (treatment in 
Diagnosis treatment in 8 days (CPZ mg ation (days) supportive days) CPZ mg equiv) 
last 7 days equiv) measures) 
(CPZ mg 
equiv) 
1 0-175 75 Bromocriptine 
2 Schizo­ 222-225 86 Bromocriptine 
phrenia Levodopa 
Carbidopa 
3 Psychosis 0-150 105 
4 Psychotic 40-1040 56 Levodopa 947 75 
Depression Carbidopa 
5 Manic 75-75 41 Levodopa 327 8 
Depressive Diazepam 
Psychosis 
6 Senile 87-217 19 Levodopa 
Dementia Carbidopa 
7 None Metoclopra 4 Levodopa 
-mide 10mg Procyclidine 
8 Acute 0-150 1258 40 ECT 
Psychosis 
9 Depressive 1850-1850 1750 25 Diazepam 305 425 
Psychosis 
10 Mental 500-500 500 57 Bromocriptine 75 
Retardation Benserazide 
Levodopa 
11 Mental 850-2350 56 Bromocriptine 7 300 
Retardation Benserazide 
with Manic Levodopa 
Depressive 
Illness 
12 Senile 0-30 500 27 Levodopa 
Dementia Carbidopa 
Table I 
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NMS during the first fourteen days of their first 
exposure to neuroleptics, one patient had 
neuroleptics prescribed for the first time four 
months prior to the NMS episode with no other 
change in treatment, and the other two patients 
had been exposed to neuroleptics for two years 
but had an increase in treatment within the last 
ten days . Three patients were having their 
neuroleptics orally, eight both orally and 
intramuscularly and one patient had just a single 
dose of intramuscular neuroleptic treatment. 
Dosage change during the last seven days prior to 
the onset of NMS is shown in Table I. Only one 
patient was being treated concomitanlly with 
lithium carbonate. 
Prior to the onset of NMS, six patients were 
agitated and dehydration was present in four 
patients. None of the patients was treated by 
means of supportive measures alone. Treatments 
used were bromocriptine, levodopa either alone 
or with benserazide hydrochloride or with 
carbidopa, ECT, intravenous procyclidine 
hydrochloride and diazepam (Table I). 
Only five patients had no complications of NMS. 
Renal impairment occurred in four patients and 
four patients needed assisted ventilation, one of 
them having lung collapse. Other complications 
of NMS were cerebral infarct in two cases, 
hypokinetic bowels in a further two cases and 
one case of deep vein thrombosis. There were no 
deaths due to NMS, however two patients have 
since died from other causes. 
Five patients are known to have been re­
prescribed neuroleptics after resolution of NMS. 
None of these developed NMS again (Table I). 
Discussion 
This study is limited in scope because it is 
retrospective and the sample is small, precluding 
meaningful statistical analysis . On the other 
hand, it constitutes the first attempt to study the 
incidence and factors related to the NMS as it 
occurs in Malta. 
Notwithstanding the retrospective nature of 
\ 
the 
study , it is reasonable to assume, given Malta's 
small size and close knit medical community, 
that no known cases were missed. It is of course 
conceivable that the clinical diagnosis may have 
been missed in some instances, particularly in the 
elderly. The calculated incidence of 0.67% in 
this study shows the frequency of NMS in Malta 
to be towards the lower end of the 0.02 - 3.23% 
range reported in other studies, 1 but it is higher 
than the 0 .15% reported in a centre which is 
trying to recognise NMS at an earlier stage and 
reduce its risk factors. 2 
As in most studies, dehydration, agitation, brain 
pathology and intramuscular neuroleptic 
administration were significant risk factors whilst 
the most common primary psyclliatric diagnosis 
was affective disorder. In our study there was no 
significant correlation between the use of lithium 
carbonate and the development of NMS. The 
fact that ten patients had an increase in 
neuroleptic dosage during the seven days prior to 
the NMS episode supports this being an 
important NMS triggering factor. The finding 
that seven of the patients had, at no stage, 
received neuroleptics at dosages greater than 225 
mg of Chlorpromazine equivalent, supports the 
view that it is the rate of the change of dosage 
rather than total dosage that is critical. 
Since none of the patients were treated with 
supportive measures alone, no conclusions can be 
drawn about the different outcomes of supportive 
measures alone versus treatment consisting also 
of medication. Renal and respiratory 
complications were as common as in other 
studies. Thromboembolic complications and 
hypokinetic bowels also occurred. Two cases 
had uncontrolled diabetes mellitus and NMS 
occurring concominantly. The high incidence of 
diabetes mellitus in Malta makes this a relevant 
corre lation. 
In this study, none of the other patients 
developing NMS were diabetic. The proportion 
of the total sample exposed to the neuroleptics 
who were diabetic is not known but because of 
the high prevalence of diabetes in Malta i.e . 
7.7%, 12 it can safely be assumed that a 
significant proportion were diabetic. Whether 
they constitute a sub-group at higher risk of 
developing NMS or its complications remains to 
be explored. 
Further, while. uncontrolled diabetes mellitus can 
be an NMS complication, it is also possible that 
the uncontrolled diabetic state can precipitate 
NMS, either by some direct effect or through 
resultant dehydration. Balzan and Cacciottolo, II 
suggest that uncontrolled diabetes mellitus 
together with dehydration may precipitate NMS 
in diabetic patients on neuroleptics and further 
that the hypermetabolic state in NMS may cause 
ketotic or non-ketotic diabetic coma in 
previously well controlled diabetics. 
Two out of five patients re-challenged with 
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neuroleptics were within the two week suggested 
danger time interval after the resolution of the 
NMS episode. All patients re-challenged 
recei ved less potent treatment than that prior to 
the NMS episode (Table I) . This could be an 
important reason why none of the patients had 
further episodes of NMS . 
Conclusions 
Our sample of twelve patients is too small to 
draw any statistically significant conclusions, 
however the results are mostly in line with those t 
obtained from larger samples. The incidence, 
which is higher than that reported in centres 
which are trying to recognise NMS at an earlier 
stage and reduce risk factors, suggests that Malta 
could benefit from trying to adopt such measures. 
Given Malta's small size it would be relatively 
easy to disseminate such information. Keck et al 
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describe the following measures for the early 
detection of NMS 2 : 
• Increasing clinical awareness of the 
cardinal features of NMS 
• Treating neuroleptic induced 
extrapyramidal and autonomic side effects 
at their earliest emergence 
• Minimizing risk factors such as use of 
intramuscular neuroleptics 
The other noteworthy point is the previously 
reported association of non-ketotic diabetic coma 
with NMS .ll Our study, despite its 
comprehensive sample, did not reveal any other 
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demonstrated that diabetics were at higher risk of 
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